You are here

Phase 2 Study Evaluates Squalamine Lactate in Wet Age-Related Macular Degeneration

PLYMOUTH MEETING, Pa., June 26 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today announced that the first patient has been enrolled in a multi-center, open-label, pharmacodynamic Phase II clinical trial, MSI-1256F-212 ("Study 212"), to explore the efficacy and safety of EVIZON(TM) (squalamine lactate) at higher doses. Study 212 is designed to evaluate up to 140 patients with wet age-related macular degeneration ("AMD") treated with EVIZON(TM) at four dose levels (40 mg, 80 mg, 120 mg and 160 mg) over a 20 week period.

"Genaera is pleased to announce the beginning of active enrollment in Study 212," commented Jack Armstrong, President and Chief Executive Officer. "We have assembled an outstanding group of investigators and study sites and are looking forward to obtaining additional information on the most effective dose of EVIZON. This study will provide more detailed information on EVIZON's effects on visual acuity in both affected eyes of patients with exudative AMD. There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections. EVIZON is differentiated from other competitor drugs having demonstrated a positive effect in both study and fellow affected eyes in previous clinical trials. We look forward to confirming that EVIZON is the treatment to meet that medical need."

For information about participation in EVIZON(TM) clinical trials, patients and physicians may call Genaera's Clinical Trial Hotline at (800) 299-9156.

Source: Genaera Corporation

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs